SecurityROSE / Rosehill Resources Inc.
Institutional Buyers10
Opened Positions2
Related ROSEU / Rosehill Resources
ROSEW / Rosehill Resources, Warrants

Institutional and Fund Ownership - Buyers

Major holders that have opened new positions in ROSE / Rosehill Resources Inc. include Strs Ohio, and Piedmont Investment Advisors Llc.

This page shows changes in the ownership structure by listing institutions, funds, and major shareholders that have increased their holdings or opened new positions in the last reporting period. Green rows indicate new positions. Click the link icon to see the full transaction history.

File DateFormInvestor Prev Shares Shares Change
Prev Value
Current Value (x$1000) Change
2018‑08‑14 13F-HR UBS Group AG 0 5,149 0 42
2018‑08‑06 13F-HR STRS OHIO 4,500 36
2018‑08‑14 13F-HR JP Morgan Chase & Co 508 131,237 25,734.06 3 1,066 35,433.33
2018‑08‑10 13F-HR CITIGROUP INC 1 1,624 162,300.00 0 13
2018‑08‑14 13F-HR QUANTUM CAPITAL MANAGEMENT 214,442 256,114 19.43 1,259 2,080 65.21
2018‑08‑14 13F-HR BANK OF AMERICA CORP /DE/ 221 6,475 2,829.86 1 52 5,100.00
2018‑08‑13 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 12,801 16,884 31.90 75 137 82.67
2018‑08‑14 13F-HR VANGUARD GROUP INC 120,690 165,052 36.76 709 1,340 89.00
2018‑08‑14 13F-HR ROYAL BANK OF CANADA 1 2 100.00 0 0

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 777385105